Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...

I last updated on Viking Therapeutics, Inc. (VKTX) in October last year, covering the company's Q3 earnings and business updates, and issued stock with a Buy rating - my sixth straight Buy call, in ...

Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, following the positive ...

Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront with ...

Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...

The MarketWatch News Department was not involved in the creation of this content. 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 ...

VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...

SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...